---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-066631"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2026-05-27T13:01:19+00:00"
generated_at: "2026-05-27T13:02:21.692349+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MetaVia announces Phase 1 data: DA-1726 48 mg yields 9.1% weight loss at Day 54 without plateau

## Summary
- 48 mg cohort achieved 9.1% mean body weight reduction at Day 54; no plateau through Week 8.
- Exploratory FibroScan showed liver improvements: CAP -20.0 dB/m vs +24.0 placebo; liver stiffness -10.3% vs +13.8%.
- No serious adverse events or treatment-related discontinuations; GI events mild-to-moderate and transient.
- Waist circumference reduced by 9.8 cm at Day 54 (p<0.05 vs placebo at Day 26).
- Ongoing Phase 1 Part 3a/3b titration studies evaluate extended treatment at higher doses.

## SEC filing metadata
- accession: 0001104659-26-066631
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2026-05-27T13:01:19+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000110465926066631/0001104659-26-066631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000110465926066631/mtva-20260527x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-066631
- JSON: https://secwatch.observer/filing/0001104659-26-066631.json
- Plain text: https://secwatch.observer/filing/0001104659-26-066631.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.